Tables
- TABLE 1
Summary of the main areas of application of low-dose, long-term macrolides in diffuse interstitial lung diseases (ILDs)
Macrolide uses and functions Evidence type First author [ref.] In ILDs, including idiopathic pulmonary fibrosis Macrolides may play an antifibrotic role Still to be demonstrated in human models Promoters of autophagocytosis and clearance of intracellular protein aggregates Only cellular models Guillot [1]
Thomson [8]
Stamatiou [9]Regulators of surfactant homeostasis One case report Thouvenin [10] Macrolides may act as host–microbiota interaction modulators and/or host immune response modulators Still to be demonstrated in human models Reduction of acute exacerbations rate Retrospective monocentric study Kuse [33] In organising pneumonia Macrolides may exert an anti-inflammatory/immunomodulatory action Case reports and case series As adjuvants to steroid therapy and steroid-sparing agents One case report Ding [51] As first-line agents as an alternative to steroids Case reports and case series Ichikawa [45]
Stover [46]
Hotta [49]
Radzikowska [44]As second-line agents when steroids are not tolerated or failed Case reports and case series Chang [52]
Stover [46]
Pathak [53]
Vol 26 Issue 146
Table of Contents
Long-term macrolides in diffuse interstitial lung diseases
